No current GLP-1 label lists weight regain after bariatric surgery as an approved use, so prescribing one for it would be off-label. BARI-STEP (Semaglutide): At least a year after surgery, in people who had lost less than hoped, weight changed -18.0% on semaglutide 2.4 mg against +0.4% on placebo over 68 weeks. ClinicalTrials.gov lists 50 trials of these medicines on it: 4 with posted results and 11 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 2, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 70 people · Better than the comparison · Placebo-controlled randomized trial
At least a year after surgery, in people who had lost less than hoped, weight changed -18.0% on semaglutide 2.4 mg against +0.4% on placebo over 68 weeks.
Liraglutide · 70 people · Better than the comparison · Placebo-controlled randomized trial
In people with poor weight loss after metabolic surgery and a suboptimal GLP-1 response, weight changed -8.82% on liraglutide 3 mg against -0.54% on placebo over 24 weeks.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 24 | 1 | 9 |
| Liraglutide | 16 | 3 | 1 |
| Tirzepatide | 6 | 0 | 1 |
| Exenatide | 3 | 0 | 0 |
| Mazdutide | 1 | 0 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT03115424Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | Liraglutide | Phase 3 | 46 | Weight (kilograms), baseline and 36 months, baseline. Sleeve Gastrectomy Saxenda: 127; Sleeve Gastrectomy Placebo: 130; Roux-en-Y Gastric (RYGB): 126. |
| NCT03048578Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery | Liraglutide | Phase 4 | 132 | Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test (percentage of participants), 12 Months. Saxenda: 76; Placebo: 17. |
| NOVO-GLP1Treatment of GLP-1 for Diabetic Bariatric Patients | Semaglutide | Phase 4 | 3 | On ClinicalTrials.gov |
| NCT04883346Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Liraglutide | Phase 2 | 34 | On ClinicalTrials.gov |
The registry page names each site and who can enroll. Ask your clinician before joining one.
Randomized trial · Diabetes Obes Metab · Oct 12, 2026 · Yang W et al.
Meta-analysis · Zhonghua Wei Chang Wai Ke Za Zhi · Oct 1, 2026 · He MC et al.
Meta-analysis · Endocrinol Diabetes Metab · Sep 1, 2026 · Shirmohammadi E et al.
Meta-analysis · Surg Obes Relat Dis · Jul 29, 2026 · Campbell C et al.
Meta-analysis · J Laparoendosc Adv Surg Tech A · Jul 14, 2026 · Rivero-Moreno Y et al.
Meta-analysis · Acta Diabetol · Jun 23, 2026 · Arora S et al.
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
BARI-STEP (Semaglutide, 70 people): At least a year after surgery, in people who had lost less than hoped, weight changed -18.0% on semaglutide 2.4 mg against +0.4% on placebo over 68 weeks.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 24 registered trials on it, then Liraglutide with 16. More trials do not mean better results: read what each posted.
11 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.